Transurethral electrovaporisation of the prostate is used to treat benign prostatic obstruction (BPO). BPO is a non-malignant enlargement of the prostate and is a common cause of lower urinary tract ...

Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...

Some studies show that use of transurethral resection of the prostate, long the gold standard for managing enlarged prostates, is in decline, but it still remains the most popular choice among ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...

A person may need surgery for bladder cancer to remove the tumor. A person may also need preoperative or postoperative treatments. Bladder cancer occurs when cells of the bladder start to grow out of ...

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results We conducted a prospective ...

Evidence-based recommendations on transurethral electrovaporisation of the prostate (TURP) to treat benign prostatic obstruction (BPO). This involves using a high-voltage electrical current to ...